The clinicopathological characteristics of patients in the three different treatment cohort
| Characteristics | Neoadjuvant chemoimmunotherapy (%) | Neoadjuvant chemotherapy (%) | Treatment naïve (%) | P value |
| Gender | ||||
| Male | 25(62.5) | 32 (78.0) | 22 (55.0) | 0.084 |
| Female | 15(37.5) | 9 (22.0) | 18 (45.0) | |
| Age | ||||
| <63 | 19 (47.5) | 23 (56.1) | 22 (55.0) | 0.702 |
| ≥63 | 21 (52.5) | 18 (43.9) | 18 (45.0) | |
| Smoking history | ||||
| Smoker or ex-smoker | 30 (75.0) | 33 (80.5) | 26 (65.0) | 0.278 |
| Never smoker | 10 (25.0) | 8 (19.5) | 14 (35.0) | |
| Histology | ||||
| Squamous cell carcinoma | 21 (52.5) | 25 (61.0) | 14 (35.0) | 0.111 |
| Adenocarcinoma | 15 (37.5) | 14 (34.1) | 24 (60.0) | |
| Large cell carcinoma | 4 (10.0) | 2 (4.9) | 2 (5.0) | |
| N stage | ||||
| N0 | 29 (72.5) | 24 (58.5) | 28 (70.0) | 0.361 |
| N1-2 | 11 (27.5) | 17 (41.5) | 12 (30.0) | |
| Neoadjuvant therapy no of cycles | ||||
| 2 | 16 (40.0) | 25 (61.0) | -- | 0.059 |
| >2 | 24 (60.0) | 16 (39.0) | -- | |
| EGFR mutation status | ||||
| Mutation-positive | 0 (0) | 2 (4.9) | 4 (10) | 0.106 |
| Mutation-negative | 9 (22.5) | 5 (12.2) | 11 (27.5) | |
| Unknown | 31 (77.5) | 34 (82.9) | 25 (62.5) | |